Research progress on the role of activin A in renal diseases

doi:10.3877/cma.j.issn.2095-3216.2022.01.009

Abstract

Abstract:

Activin A (ActA) is a member of the transforming growth factor-β family, and is a widely-expressed factor in the body that participates in the cell differentiation, proliferation, and inflammation. In recent years, ActA has been found to be closely related to the occurrence and development of various kidney diseases. ActA antagonists may have the effects of preventing and treating kidney disease and its complications, and delaying the progression of kidney disease. Therefore, ActA may become a new therapeutic target for kidney disease. This article summarized the latest research on the role of ActA in various types of kidney disease and kidney injury, so as to provide a reference for further exploration of ActA.

Key words: Activin A, Antagonist, Nephrotic syndrome, Acute kidney injury, Chronic kidney disease

Dong Wang, Yawei Zhang, Xiaotong Ding, Jie Ni. Research progress on the role of activin A in renal diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(01): 48-51.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.01.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I01/48

Figures/Tables 1

References 31

[1]	Walton KL, Makanji Y, Harrison CA. New insights into the mechanisms of activin action and inhibition [J]. Mol Cell Endocrinol, 2012, 359(1-2): 2-12.
[2]	Bloise E, Ciarmela P, Dela Cruz C, et al. Activin A in mammalian physiology [J]. Physiol Rev, 2019, 99(1): 739-780.
[3]	Maeshima A, Miya M, Mishima K, et al. Activin A: autocrine regulator of kidney development and repair [J]. Endocr J, 2008, 55(1): 1-9.
[4]	Maeshima A, Vaughn DA, Choi Y, et al. Activin A is an endogenous inhibitor of ureteric bud outgrowth from the Wolffian duct [J]. Dev Biol, 2006, 295(2): 473-485.
[5]	任玮，余宏川，王萍，等. miR-17-5p诱导小鼠肾足细胞系凋亡[J]. 基础医学与临床，2019, 39(7): 973-977.
[6]	张延蕊，武艺飞，王慧，等. 微小RNA-17-5p在小儿肾病综合征发病中的作用及其机制研究[J]. 中国当代儿科杂志，2020, 22(9): 958-963.
[7]	Takahashi S, Nakasatomi M, Takei Y, et al. Identification of urinary activin A as a novel biomarker reflecting the severity of acute kidney injury [J]. Sci Rep, 2018, 8(1): 5176.
[8]	Tsai YL, Chou RH, Lu YW, et al. Serum activin A levels and renal outcomes after coronary angiography [J]. Sci Rep, 2020, 10(1): 3365.
[9]	Jelkmann W. Activin receptor ligand traps in chronic kidney disease [J]. Curr Opin Nephrol Hypertens, 2018, 27(5): 351-357.
[10]	Spottiswoode N, Armitage AE, Williams AR, et al. Role of activins in hepcidin regulation during malaria [J]. Infect Immun, 2017, 85(12): e00191-17.
[11]	Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin [J]. Br J Haematol, 2014, 165(6): 870-882.
[12]	Mehta N, Krepinsky JC. The emerging role of activins in renal disease [J]. Curr Opin Nephrol Hypertens, 2020, 29(1): 136-144.
[13]	Hortells L, Sosa C, Guillén N, et al. Identifying early pathogenic events during vascular calcification in uremic rats [J]. Kidney Int, 2017, 92(6): 1384-1394.
[14]	Sugatani T. Systemic activation of activin A signaling causes chronic kidney disease-mineral bone disorder [J]. Int J Mol Sci, 2018, 19(9): 2490.
[15]	Sugatani T, Agapova OA, Fang Y, et al. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease [J]. Kidney Int, 2017, 91(1): 86-95.
[16]	Lima F, Mawad H, El-Husseini AA, et al. Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers [J]. Clin Nephrol, 2019, 91(4): 222-230.
[17]	Nordholm A, Mace ML, Gravesen E, et al. Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney [J]. Am J Physiol Renal Physiol, 2018, 314(5): F753-F762.
[18]	Nordholm A, Egstrand S, Gravesen E, et al. Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats [J]. Pflugers Arch, 2019, 471(8): 1079-1094.
[19]	Wang Y, He G, Tang H, et al. Aspirin inhibits inflammation and scar formation in the injury tendon healing through regulating JNK/STAT-3 signalling pathway [J]. Cell Prolif, 2019, 52(4): e12650.
[20]	Zhang D, Gava AL, Van Krieken R, et al. The caveolin-1 regulated protein follistatin protects against diabetic kidney disease [J]. Kidney Int, 2019, 96(5): 1134-1149.
[21]	Bian X, Griffin TP, Zhu X, et al. Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy [J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000720.
[22]	Kadiombo AT, Maeshima A, Kayakabe K, et al. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice [J]. Am J Physiol Renal Physiol, 2017, 312(2): F297-F304.
[23]	Takei Y, Takahashi S, Nakasatomi M, et al. Urinary activin A is a novel biomarker reflecting renal inflammation and tubular damage in ANCA-associated vasculitis [J]. PLoS One, 2019, 14(10): e0223703.
[24]	Iriuchishima H, Maeshima A, Takahashi S, et al. Activin A: a novel urinary biomarker of renal impairment in multiple myeloma [J]. Biosci Rep, 2019, 39(5): BSR20190206.
[25]	Koken E, Oyar EO, Uyanikgil Y, et al. Exogenous follistatin administration ameliorates cisplatin-induced acute kidney injury through anti-inflammation and anti-apoptosis effects [J]. Bratisl Lek Listy, 2020, 121(2): 143-150.
[26]	Yuan C, Ni L, Wu X. Activin A activation drives renal fibrosis through the STAT3 signaling pathway [J]. Int J Biochem Cell Biol, 2021, 134: 105950.
[27]	Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study [J]. Haematologica, 2019, 104(3): 477-484.
[28]	Komrokji RS. Activin receptor II ligand traps: new treatment paradigm for low-risk MDS [J]. Curr Hematol Malig Rep, 2019, 14(4): 346-351.
[29]	Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma [J]. Br J Haematol, 2014, 165(6): 814-823.
[30]	Agapova OA, Fang Y, Sugatani T, et al. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease [J]. Kidney Int, 2016, 89(6): 1231-1243.
[31]	Williams MJ, Sugatani T, Agapova OA, et al. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease [J]. Kidney Int, 2018, 93(1): 147-158.

Please choose a citation manager

Content to export